Literature DB >> 26462551

Design, synthesis, biological evaluation and X-ray structural studies of HIV-1 protease inhibitors containing substituted fused-tetrahydropyranyl tetrahydrofuran as P2-ligands.

Arun K Ghosh1, Cuthbert D Martyr, Luke A Kassekert, Prasanth R Nyalapatla, Melinda Steffey, Johnson Agniswamy, Yuan-Fang Wang, Irene T Weber, Masayuki Amano, Hiroaki Mitsuya.   

Abstract

Design, synthesis, biological and X-ray crystallographic studies of a series of potent HIV-1 protease inhibitors are described. Various polar functionalities have been incorporated on the tetrahydropyranyl-tetrahydrofuran-derived P2 ligand to interact with the backbone atoms in the S2-subsite. The majority of the inhibitors showed very potent enzyme inhibitory and antiviral activity. Two high-resolution X-ray structures of 30b- and 30j-bound HIV-1 protease provide insight into ligand-binding site interactions. In particular, the polar functionalities on the P2-ligand appear to form unique hydrogen bonds with Gly48 amide NH and amide carbonyl groups in the flap region.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26462551      PMCID: PMC4666783          DOI: 10.1039/c5ob01930c

Source DB:  PubMed          Journal:  Org Biomol Chem        ISSN: 1477-0520            Impact factor:   3.876


  29 in total

1.  PRODRG: a tool for high-throughput crystallography of protein-ligand complexes.

Authors:  Alexander W Schüttelkopf; Daan M F van Aalten
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2004-07-21

2.  Mitsunobu and related reactions: advances and applications.

Authors:  K C Kumara Swamy; N N Bhuvan Kumar; E Balaraman; K V P Pavan Kumar
Journal:  Chem Rev       Date:  2009-06       Impact factor: 60.622

3.  Design of HIV-1 protease inhibitors with C3-substituted hexahydrocyclopentafuranyl urethanes as P2-ligands: synthesis, biological evaluation, and protein-ligand X-ray crystal structure.

Authors:  Arun K Ghosh; Bruno D Chapsal; Garth L Parham; Melinda Steffey; Johnson Agniswamy; Yuan-Fang Wang; Masayuki Amano; Irene T Weber; Hiroaki Mitsuya
Journal:  J Med Chem       Date:  2011-07-29       Impact factor: 7.446

4.  Disubstituted Bis-THF Moieties as New P2 Ligands in Nonpeptidal HIV-1 Protease Inhibitors (II).

Authors:  Konrad Hohlfeld; Jörg Kurt Wegner; Bart Kesteleyn; Bruno Linclau; Johan Unge
Journal:  J Med Chem       Date:  2015-04-30       Impact factor: 7.446

5.  A simple, continuous fluorometric assay for HIV protease.

Authors:  M V Toth; G R Marshall
Journal:  Int J Pept Protein Res       Date:  1990-12

6.  Probing multidrug-resistance and protein-ligand interactions with oxatricyclic designed ligands in HIV-1 protease inhibitors.

Authors:  Arun K Ghosh; Chun-Xiao Xu; Kalapala Venkateswara Rao; Abigail Baldridge; Johnson Agniswamy; Yuan-Fang Wang; Irene T Weber; Manabu Aoki; Salcedo Gomez Pedro Miguel; Masayuki Amano; Hiroaki Mitsuya
Journal:  ChemMedChem       Date:  2010-11-08       Impact factor: 3.466

7.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

8.  Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro.

Authors:  Yasuhiro Koh; Hirotomo Nakata; Kenji Maeda; Hiromi Ogata; Geoffrey Bilcer; Thippeswamy Devasamudram; John F Kincaid; Peter Boross; Yuan-Fang Wang; Yunfeng Tie; Patra Volarath; Laquasha Gaddis; Robert W Harrison; Irene T Weber; Arun K Ghosh; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

9.  Demonstration of sustained drug-resistant human immunodeficiency virus type 1 lineages circulating among treatment-naïve individuals.

Authors:  Stéphane Hué; Robert J Gifford; David Dunn; Esther Fernhill; Deenan Pillay
Journal:  J Virol       Date:  2009-01-21       Impact factor: 5.103

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more
  3 in total

1.  Potent antiviral HIV-1 protease inhibitor combats highly drug resistant mutant PR20.

Authors:  Daniel W Kneller; Johnson Agniswamy; Arun K Ghosh; Irene T Weber
Journal:  Biochem Biophys Res Commun       Date:  2019-08-29       Impact factor: 3.575

2.  Novel Protease Inhibitors Containing C-5-Modified bis-Tetrahydrofuranylurethane and Aminobenzothiazole as P2 and P2' Ligands That Exert Potent Antiviral Activity against Highly Multidrug-Resistant HIV-1 with a High Genetic Barrier against the Emergence of Drug Resistance.

Authors:  Yuki Takamatsu; Manabu Aoki; Haydar Bulut; Debananda Das; Masayuki Amano; Venkata Reddy Sheri; Ladislau C Kovari; Hironori Hayashi; Nicole S Delino; Arun K Ghosh; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

3.  Nature Inspired Molecular Design: Stereoselective Synthesis of Bicyclic and Polycyclic Ethers for Potent HIV-1 Protease Inhibitors.

Authors:  Arun K Ghosh; Margherita Brindisi
Journal:  Asian J Org Chem       Date:  2018-06-08       Impact factor: 3.319

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.